JP6005656B2 - ベンゾイミダゾール呼吸合胞体ウイルス阻害剤 - Google Patents

ベンゾイミダゾール呼吸合胞体ウイルス阻害剤 Download PDF

Info

Publication number
JP6005656B2
JP6005656B2 JP2013543799A JP2013543799A JP6005656B2 JP 6005656 B2 JP6005656 B2 JP 6005656B2 JP 2013543799 A JP2013543799 A JP 2013543799A JP 2013543799 A JP2013543799 A JP 2013543799A JP 6005656 B2 JP6005656 B2 JP 6005656B2
Authority
JP
Japan
Prior art keywords
compound
compound according
compounds
formula
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013543799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013545785A (ja
JP2013545785A5 (cg-RX-API-DMAC7.html
Inventor
コーイマン,ルートビヒ・ポール
ドマン,サミユエル・ドミニク
フー,リリ
ヨンカース,テイム・ヒユーゴ・マリア
ラボワソン,ピエール・ジヤン−マリー・ベルナール
ターリ,アブデラー
バンドビル,サンドリーヌ・マリー・エレーヌ
Original Assignee
ヤンセン・サイエンシズ・アイルランド・ユーシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43875271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6005656(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ヤンセン・サイエンシズ・アイルランド・ユーシー filed Critical ヤンセン・サイエンシズ・アイルランド・ユーシー
Publication of JP2013545785A publication Critical patent/JP2013545785A/ja
Publication of JP2013545785A5 publication Critical patent/JP2013545785A5/ja
Application granted granted Critical
Publication of JP6005656B2 publication Critical patent/JP6005656B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013543799A 2010-12-16 2011-12-16 ベンゾイミダゾール呼吸合胞体ウイルス阻害剤 Expired - Fee Related JP6005656B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10195467.5 2010-12-16
EP10195467 2010-12-16
PCT/EP2011/073008 WO2012080446A1 (en) 2010-12-16 2011-12-16 Benzimidazole respiratory syncytial virus inhibitors

Publications (3)

Publication Number Publication Date
JP2013545785A JP2013545785A (ja) 2013-12-26
JP2013545785A5 JP2013545785A5 (cg-RX-API-DMAC7.html) 2014-06-26
JP6005656B2 true JP6005656B2 (ja) 2016-10-12

Family

ID=43875271

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013543799A Expired - Fee Related JP6005656B2 (ja) 2010-12-16 2011-12-16 ベンゾイミダゾール呼吸合胞体ウイルス阻害剤

Country Status (30)

Country Link
US (1) US8865705B2 (cg-RX-API-DMAC7.html)
EP (1) EP2651903B1 (cg-RX-API-DMAC7.html)
JP (1) JP6005656B2 (cg-RX-API-DMAC7.html)
KR (1) KR101876240B1 (cg-RX-API-DMAC7.html)
CN (2) CN107417683A (cg-RX-API-DMAC7.html)
AR (1) AR085203A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011343255B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013012137A2 (cg-RX-API-DMAC7.html)
CA (1) CA2821999C (cg-RX-API-DMAC7.html)
CL (1) CL2013001713A1 (cg-RX-API-DMAC7.html)
CY (1) CY1117751T1 (cg-RX-API-DMAC7.html)
DK (1) DK2651903T3 (cg-RX-API-DMAC7.html)
EA (1) EA022972B1 (cg-RX-API-DMAC7.html)
ES (1) ES2576180T3 (cg-RX-API-DMAC7.html)
HK (1) HK1247616A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20160650T1 (cg-RX-API-DMAC7.html)
HU (1) HUE029247T2 (cg-RX-API-DMAC7.html)
IL (1) IL225640A (cg-RX-API-DMAC7.html)
MX (1) MX340030B (cg-RX-API-DMAC7.html)
MY (1) MY156641A (cg-RX-API-DMAC7.html)
NZ (1) NZ609450A (cg-RX-API-DMAC7.html)
PH (1) PH12013500796A1 (cg-RX-API-DMAC7.html)
PL (1) PL2651903T3 (cg-RX-API-DMAC7.html)
PT (1) PT2651903E (cg-RX-API-DMAC7.html)
SG (1) SG190766A1 (cg-RX-API-DMAC7.html)
SI (1) SI2651903T1 (cg-RX-API-DMAC7.html)
TW (1) TWI530495B (cg-RX-API-DMAC7.html)
UA (1) UA112298C2 (cg-RX-API-DMAC7.html)
WO (1) WO2012080446A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201304424B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541241B (zh) 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類
TWI515187B (zh) * 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI501967B (zh) * 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
TWI527814B (zh) 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
TWI530495B (zh) 2010-12-16 2016-04-21 健生科學愛爾蘭無限公司 苯并咪唑呼吸道融合病毒抑制劑
EA201590020A1 (ru) * 2012-06-15 2015-03-31 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса
KR102092612B1 (ko) 2012-06-15 2020-03-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 호흡기 합포체 바이러스의 항바이러스제로서의 헤테로사이클로 치환된 1,3-디하이드로-2h-벤즈이미다졸-2-온 유도체
WO2014009302A1 (en) * 2012-07-10 2014-01-16 F. Hoffmann-La Roche Ag Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection
EP2909195B1 (en) 2012-10-16 2017-06-14 Janssen Sciences Ireland UC Rsv antiviral compounds
EA026546B1 (ru) 2013-01-28 2017-04-28 Янссен Сайенсиз Айрлэнд Юси Хиноксалиноны и дигидрохиноксалиноны как антивирусные средства против респираторно-синцитиального вируса
RU2015148926A (ru) 2013-05-14 2017-06-15 Ф. Хоффманн-Ля Рош Аг Аза-оксо-индолы для лечения и профилактики респираторно-синцитиальной вирусной инфекции
CN105392787B (zh) * 2013-05-14 2017-11-24 豪夫迈·罗氏有限公司 用于治疗和预防呼吸道合胞病毒感染的氮杂‑氧代‑吲哚
EP3033333A1 (en) 2013-08-15 2016-06-22 F. Hoffmann-La Roche AG Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
HK1225716A1 (zh) 2013-08-21 2017-09-15 Alios Biopharma, Inc. 抗病毒化合物
WO2015065336A1 (en) * 2013-10-29 2015-05-07 Medivir Ab Respiratory syncytial virus inhibitors
TWI671299B (zh) 2014-04-14 2019-09-11 愛爾蘭商健生科學愛爾蘭無限公司 作為rsv抗病毒化合物之螺脲化合物
CA2957017A1 (en) * 2014-08-05 2016-02-11 Alios Biopharma, Inc. Combination therapy for treating a paramyxovirus
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
MX381798B (es) 2015-07-22 2025-03-13 Enanta Pharm Inc Derivados de benzodiazepina como inhibidores de rsv
EP3402799B1 (en) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
CN110809472B (zh) 2017-02-16 2023-05-23 英安塔制药有限公司 用于制备苯二氮䓬衍生物的方法
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
US10881666B2 (en) 2017-09-29 2021-01-05 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as RSV inhibitors
JP7228588B2 (ja) 2017-11-13 2023-02-24 エナンタ ファーマシューティカルズ インコーポレイテッド ベンゾジアゼピン-2-オンおよびベンゾアゼピン-2-オン誘導体の分割方法
BR112021018335A2 (pt) 2019-03-18 2021-11-23 Enanta Pharm Inc Derivados de benzodiazepina como inibidores de rsv
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
TWI864048B (zh) 2019-10-04 2024-12-01 美商安塔製藥公司 抗病毒雜環化合物、其醫藥組成物及其用途
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
US12145933B2 (en) 2020-06-11 2024-11-19 Janssen Sciences Ireland Unlimited Company Hemi (L)-tartrate forms of 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethy)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one and pharmaceutical compositions comprising the same
WO2022010882A1 (en) 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
WO2022182861A1 (en) 2021-02-26 2022-09-01 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
WO2023211997A1 (en) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Antiviral compounds
WO2024174953A1 (zh) * 2023-02-21 2024-08-29 苏州隆博泰药业有限公司 苯并咪唑类衍生物及其医药用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514162A (ja) 1996-07-08 2002-05-14 デュポン ファーマシューティカルズ カンパニー Xa因子阻害薬およびトロンビン阻害薬としてのアミジノインドール類、アミジノアゾール類、およびそれらの類似体
AU1099000A (en) 1998-10-05 2000-04-26 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
TR200103804T2 (tr) 1999-06-28 2002-05-21 Janssen Pharmaceutica N.V. Solunum sistemi sinsitiyal virüsünün replikasyonunu inhibe edici maddeler
EE04591B1 (et) 1999-06-28 2006-02-15 Janssen Pharmaceutica N.V. Respiratoorse süntsütiaalviiruse replikatsiooni inhibiitorid, nende valmistamismeetod, kasutamine ja vaheühendid, farmatseutiline kompositsioon ja selle valmistamismeetod ning produkt
US6534535B1 (en) 1999-08-12 2003-03-18 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6489338B2 (en) * 2000-06-13 2002-12-03 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrimidine antiviral agents
US6506738B1 (en) 2000-09-27 2003-01-14 Bristol-Myers Squibb Company Benzimidazolone antiviral agents
US6919331B2 (en) * 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
WO2004043913A2 (en) 2002-11-08 2004-05-27 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
TWI515187B (zh) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI530495B (zh) 2010-12-16 2016-04-21 健生科學愛爾蘭無限公司 苯并咪唑呼吸道融合病毒抑制劑
TWI541241B (zh) 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類
TWI527814B (zh) 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類

Also Published As

Publication number Publication date
AU2011343255B2 (en) 2014-12-11
TWI530495B (zh) 2016-04-21
EA201390888A1 (ru) 2013-12-30
SI2651903T1 (sl) 2016-07-29
CA2821999C (en) 2019-02-26
EP2651903B1 (en) 2016-03-23
HK1247616A1 (zh) 2018-09-28
CN103313974A (zh) 2013-09-18
PT2651903E (pt) 2016-06-17
PL2651903T3 (pl) 2016-10-31
BR112013012137A2 (pt) 2016-08-16
PH12013500796A1 (en) 2013-06-24
UA112298C2 (uk) 2016-08-25
NZ609450A (en) 2014-10-31
SG190766A1 (en) 2013-07-31
CA2821999A1 (en) 2012-06-21
EP2651903A1 (en) 2013-10-23
CN107417683A (zh) 2017-12-01
HRP20160650T1 (hr) 2016-07-15
ES2576180T3 (es) 2016-07-06
AU2011343255A1 (en) 2013-05-02
MX340030B (es) 2016-06-21
WO2012080446A1 (en) 2012-06-21
AR085203A1 (es) 2013-09-18
US20130267508A1 (en) 2013-10-10
JP2013545785A (ja) 2013-12-26
US8865705B2 (en) 2014-10-21
IL225640A (en) 2015-02-26
CL2013001713A1 (es) 2013-10-11
KR20140025321A (ko) 2014-03-04
ZA201304424B (en) 2014-12-23
MX2013006886A (es) 2013-07-05
DK2651903T3 (da) 2016-06-27
TW201305142A (zh) 2013-02-01
CY1117751T1 (el) 2017-05-17
HUE029247T2 (en) 2017-02-28
IL225640A0 (en) 2013-06-27
KR101876240B1 (ko) 2018-08-02
EA022972B1 (ru) 2016-03-31
MY156641A (en) 2016-03-15

Similar Documents

Publication Publication Date Title
JP6005656B2 (ja) ベンゾイミダゾール呼吸合胞体ウイルス阻害剤
TWI515187B (zh) 作為呼吸道融合病毒抗病毒劑之吲哚類
JP5876501B2 (ja) 呼吸合胞体ウイルスの抗ウイルス剤としてのアザベンゾイミダゾール
JP5876502B2 (ja) 呼吸合胞体ウイルスの抗ウイルス剤としてのアザインドール
JP5876503B2 (ja) 呼吸合胞体ウイルスの抗ウイルス剤としてのイミダゾピリジン
JP6383735B2 (ja) Rsウイルスの抗ウイルス剤としてのキノキサリノンおよびジヒドロキノキサリノン
JP2015523350A (ja) Rsウイルス抗ウイルス薬としての、ベンゾイミダゾールによって置換された新規1,3−ジヒドロ−2h−ベンゾイミダゾル−2−オン誘導体
EP2864323B1 (en) 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
JP2015519385A (ja) Rsウイルス抗ウイルス薬としての、ベンゾイミダゾールによって置換された新規4−置換1,3−ジヒドロ−2h−ベンゾイミダゾル−2−オン誘導体
JP2015519387A (ja) Rsウイルス抗ウイルス薬としての、複素環によって置換された新規4−置換1,3−ジヒドロ−2h−ベンゾイミダゾル−2−オン誘導体
HK1185065A (en) Benzimidazole respiratory syncytial virus inhibitors
HK1185613B (en) Indoles as respiratory syncytial virus antiviral agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141215

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150617

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160406

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160719

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160810

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160907

R150 Certificate of patent or registration of utility model

Ref document number: 6005656

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees